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Dermatological Aspects of COVID-19
Introduction:
 On 31 December 2019, Wuhan, the capital city 
of Hubei Province in China reported World Health 
Organization(WHO) about cases of pneumonia 
which were caused by a severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2)[1] currently 
designated coronavirus disease (COVID-19).[2] 
The infection rapidly spread throughout the world 
escalating the situation and WHO eventually declared 
COVID-19 as a global pandemic on 11 March 2020.
[3] It has already affected almost all aspects of health 
and society globally. With the current pandemic, 
dermatologists should be aware of dermatological 
aspects of SARS-CoV-2, its skin manifestations and 
general skin care.
Cutaneous manifestations in COVID-19 patients:
 The SARS-Cov-2 primarily affects the 
respiratory system, but currently numerous 
cutaneous manifestations of this viral infection are 
reported.[4] Incidence of cutaneous manifestations 
among confirmed COVID-19 cases was 20.4% 
among total 88 COVID-19 patients as per an Italian 
study conducted by Recalcati et al.[4]  The trunk was 
the main involved region, pruritus was minimal and 
usually lesions healed within a few days. The study 
reported no correlation of cutaneous manifestations 
with disease severity. A recent study done in Spain 
has classified cutaneous features of COVID-19 as 
Acral areas of erythema with vesicles or pustules 
(Pseudo‐chilblain or Covid toes), vesicular eruptions, 
urticarial lesions, maculopapular eruptions and 
livedo or necrosis. A commonly observed cutaneous 
feature was maculopapular or morbilliform rash in 
47% of cases among 375 cases.[5] The timing of 
eruption of skin lesion ranged from three days before 
COVID-19 diagnosis to 13 days after diagnosis 
and lesion usually healed within 14 days.[6] The 
mechanism of cutaneous disturbances by COVID-19 
is not yet properly understood but some theories 
postulate that viral particles present in the cutaneous 
blood vessels in patients could lead to a lymphocytic 
vasculitis induced by blood immune complexes 
that activate cytokines. The virus does not directly 
target the keratinocyte, but rather immune response 
to infection leads to Langerhans cells activation, 
resulting in a state of vasodilatation and spongiosis. 
It was also suggested that livedo reticularis could 
probably be due to the accumulation of micro 
thromboses originating in other organs.[6]
 In Nepal, COVID-19 positive cases are 
increasing rapidly. The dermatologists must be aware 
of and cautious about skin lesions and the possibility 
of COVID-19 infection for prompt diagnosis and 
appropriate management. However, these rashes must 
be differentiated from drug rashes due to antivirals 
or other drugs used for the disease. It is desirable that 
physicians be aware of cutaneous manifestations 
for prevention of misdiagnosis. Joob B et al. from 
Thailand reported a case initially diagnosed as 
dengue based on skin rash with petechiae, which 
was later confirmed to be COVID-19.[7] Similarly, 
the clinical features of COVID-19 in younger age 
group may overlap with Kawasaki disease.[8] As the 
incubation period of COVID-19 is around 14 days, 
during which most of the cases are asymptomatic, 
knowledge of cutaneous manifestations may help as 
an early indicator for timely diagnosis especially in 
countries like ours with limited available tests.[2,6]
Patients suffering from skin disease receiving 
immunosuppressive medications:
 In patients with no other co-morbidities, there 
is little specific evidence of COVID-19 infection 
being aggravated by immunomodulators, but a 
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precaution must be taken as any secondary bacterial 
infection as part of COVID-19 may be aggravated by 
its concurrent use.[9] 
 American Academy of Dermatology (AAD) 
recommends that patients should not stop their 
ongoing systemic immunosuppressive therapy 
who have not tested positive or have no signs and 
symptoms of COVID-19, however indication, age 
and other co-morbidities should be considered and 
risk should be outweighed. For patients who have 
tested positive, AAD recommends to postpone or 
discontinue using immunosuppressive therapies.
[10] British Association of Dermatologists (BAD) 
has also provided guidelines for patients on 
immunosuppressive medications. Patients at definite 
high risk (extremely vulnerable people), who are of old 
age or with other co-morbidities, having two or more 
immunosuppressive medications should undergo 
shielding with self-isolation up to 12 weeks. Well-
controlled patients with minimal disease activity and 
no co-morbidities who are being treated with single 
agent of immunosuppressant or biologics or topical 
treatment need to maintain social distancing.[11] In 
confirmed cases of COVID-19 infection who are on 
systemic steroids for dermatological disorders, it can 
be continued with tapering doses.[9]
 The national guidelines from Society of 
Dermatologists, Venereologists and Leprologists 
of Nepal  (SODVELON) suggests discontinuation 
of immunosuppresants and immunomodulators 
like Rituximab if viral symptoms are present, 
whereas discontinuation of immunomodulator like 
Apremilast only if severe symptoms appear.[12]
 Thus, risk versus benefit ratio must be 
carefully weighed having original indication, elderly 
people and co-morbidities in mind before prescribing 
any immunomodulators or immunosuppressants 
in this era of pandemic. If possible, lowest dose 
possible or alternative drugs should be preferred and 
patients must be properly counselled about risks and 
necessity of shielding or self-isolation.
Skin problems in healthcare professionals dealing 
with COVID-19 patients:
 COVID-19 is primarily transmitted by 
droplets however transmission through surface 
contact is also not denied.[13] As skin is the first line 
of defense, maintaining integrity of skin must be of 
foremost priority to prevent contact transmission.
[14]
 In a study done in China among frontline 
health workers during this pandemic, occurrence 
of skin lesions was closely associated with the level 
of protection, working frequency and duration of 
wearing protective suits.[15] Frequent hand hygiene 
practice and prolonged wearing of gloves can make 
the skin over the hands vulnerable increasing the 
risk of allergic and irritant contact dermatitis. 
Aggravation of previous skin diseases has also been 
observed.  After prolonged contact with masks 
and goggles, skin lesions ranging from contact 
and pressure urticaria to contact dermatitis have 
been reported.[16] The heat and high humidity in 
the summer season can add to the skin problems 
associated with personal protective equipment (PPE) 
use and could possibly induce miliaria.[17]
 For the frontline workers; fewer working 
hours, well fitted and comfortable PPE, prophylactic 
dressing, preference of soap-based cleanser over 
alcohol-based hand rub and frequent moisturization 
of skin could be helpful for maintaining skin 
integrity.
Conclusion:
 With COVID-19 spreading rapidly in the 
country, all healthcare professionals need to be 
prepared for cases in the hospitals and community 
both. In our regular practice, aerosol generating 
procedures, cosmetic procedures and non-
emergency dermatologic surgical procedures can be 
postponed during this period. Out-patients are to be 
examined only after basic screening and with proper 
personal protective measures. As the duration of 
the pandemic cannot be predicted, strategies should 
be framed for future course of action including 
dermatology practice for the benefit of both patients 
and physicians. 
Conflict of interest: The author declares that no 
competing interest exists.
Funding: No funds were available for the study.  
REFERENCES:
1. World Health Organization. Naming the 
coronavirus disease (COVID-19) and the virus 
that causes it [Internet]. WHO: Geneva; 2020 
[cited 2020 June 2] Available from: https://
www.who.int/emergencies/diseases/novel-
coronavirus-2019/technical-guidance/naming-
the-coronavirus-disease-(covid-2019)-and-the-
virus-that-causes-it
2. Phelan AL, Katz R, Gostin LO. The Novel 
Coronavirus Originating in Wuhan, China: 
Challenges for Global Health Governance. 
JAMA. 2020;323(8):709-10. PMID: 31999307. 
DOI: https://doi.org/10.1001/jama.2020.1097
3. World Health Organization. Coronavirus 
disease (COVID-19) Situation Report. WHO: 
Geneva; 2020. Situation report No.: 51. [cited 
2020 May 25] Available from: https://www.
who.int/docs/default-source/coronaviruse/
situation-reports/20200311-sitrep-51-covid-19.
pdf?sfvrsn=1ba62e57_10
4. Recalcati S. Cutaneous manifestations in 
COVID‐19: a first perspective. Journal of 
The European Academy of Dermatology and 
Venereology. 2020;34(5):e212-e213. DOI: 
https://doi.org/10.1111/jdv.16387
5. Casas CG, Català A, Hernández GC, Rodríguez-
Jiménez P, Nieto DF, Lario AR, et al. 
Classification of the cutaneous manifestations 
of COVID-19: a rapid prospective nationwide 
consensus study in Spain with 375 cases. British 
Journal of Dermatology. Forthcoming 2020. 
Available from: https://onlinelibrary.wiley.com/
doi/abs/10.1111/bjd.19163
6. Sachdeva M, Gianotti R, Shah M, Lucia B, Tosi 
D, Veraldi S, et al. Cutaneous manifestations of 
COVID-19: Report of three cases and a review 
of literature. J Dermatol Sci. 2020;S0923-
1811(20)30149-3.  PMID: 32381430. PMCID: 
PMC7189855. DOI: https://doi.org/10.1016/j.
jdermsci.2020.04.011
7. Joob B, Wiwanitkit V. COVID-19 can present 
with a rash and be mistaken for dengue. J Am 
Acad Dermatol. 2020;82(5):e177. PMID: 
32213305. PMCID: PMC156802. DOI: https://
doi.org/10.1016/j.jaad.2020.03.036
8. Morand A, Urbina, D, Fabre A. COVID-19 and 
Kawasaki Like Disease: The Known-Known, 
the Unknown-Known and the Unknown-
Unknown. Preprints. Forthcoming 2020. 
Available from: https://www.preprints.org/
manuscript/202005.0160/v1
9. Rademaker M, Baker C, Foley P, Sullivan J, 
Wang C. Advice regarding COVID-19 and use 
of immunomodulators, in patients with severe 
dermatological diseases. Australas J Dermatol. 
2020;61(2):158-59. PMID: 32219857. PMCID: 
PMC7228260. DOI: https://doi.org/10.1111/
ajd.13295
10. American Academy of Dermatology. Guidance 
on the use of immunosuppressive agents 
[Internet]. United States: American Academy 
of Dermatology; 2020 [cited 2020 April 14]. 
Available from: www.aad.org/member/practice/
coronavirus/clinical-guidance/biologics
11. British Association of Dermatologist. 
Dermatology Advice Regarding Self-Isolation 
and Immunosuppressed Patients: Adults, 
Paediatrics and Young People [Internet]. London: 
British Association of Dermatologists; 2020 
[cited 2020 may 25]. Available from: https://
www.bad.org.uk/healthcare-professionals/
covid-19/covid-19-%20immunosuppressed-
patients.
12. Consensus/Policy of SODVELON on current 
COVID-19 crisis [Internet] 1st published 15th 
April 2020. Nepal: Society Of Dermatologists 
Venereologist and Leprologists, 2020 [cited 
2020 June 9] Available from: https://docs.google.
com/viewerng/viewer?url=http://sodvelon.
com/wp-content/uploads/2020/04/covid-19-
SODVELON-statement-for-Dermatological-
and-cosmetic-practice-final.pdf 
13. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, 
et al. A familial cluster of pneumonia associated 
with the 2019 novel coronavirus indicating 
person-to-person transmission: A study of a 
family cluster. Lancet. 2020;395(10223):514-23. 
PMID: 31986261. PMCID: PMC7159286. DOI: 
https://doi.org/10.1016/s0140-6736(20)30154-
9.T
14. Toncic RJ, Jakasa I, Hadzavdic SL, Goorden 
SM, Vlugt KJG, Stet FS, et al. Altered Levels of 
Sphingosine, Sphinganine and Their Ceramides 
J. Lumbini. Med. Coll. Vol 8, No 1, Jan-Jun 2020 jlmc.edu.np
Sharma A. Dermatological Aspects of COVID-19.
in Atopic Dermatitis Are Related to Skin Barrier 
Function, Disease Severity and Local Cytokine 
Milieu. Int J Mol Sci. 2020;21(6):1958.  PMID: 
32183011. PMCID: PMC7139865. DOI: https://
doi.org/10.3390/ijms21061958
15. Pei S, Xue Y, Zhao S, Alexander N, Mohamad 
G, Chen X, et al. Occupational skin conditions 
on the frontline: A survey among 484 Chinese 
healthcare professionals caring for Covid-19 
patients. J Eur Acad Dermatol Venereol. 2020; 
[Epub ahead of print]. PMID: 32362062. 
PMCID: PMC7267162. DOI: https://doi.
org/10.1111/jdv.16570
16. Lan J, Song Z, Miao X, Li H, Li Y, Dong L, 
et al. Skin damage among health care workers 
managing coronavirus disease-2019. J Am 
Acad Dermatol. 2020;82(5):1215-16. PMID: 
32171808. PMCID: PMC7194538. DOI: https://
doi.org/10.1016/j.jaad.2020.03.014
17. Jagadeesan S, Sarkar R. COVID-19 and the 
dermatologist: finding calm in the chaos. 
Pigment Int. 2020; [Epub ahead of print]. DOI: 
https://doi.org/10.4103/Pigmentinternational.
Pigmentinternational_24_20
Sharma A. Dermatological Aspects of COVID-19.
jlmc.edu.npJ. Lumbini. Med. Coll. Vol 8, No 1, Jan-Jun 2020
